Immunosuppressant diterpene compound
US5648376A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 19, 1995 |
| Grant date | Jul 15, 1997 |
| Priority date | — |
| Expiry date | Jan 19, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12P17/181
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
An immunosuppressant compound is produced having the structure: ##STR1## or a mirror image thereof, wherein X.sub.1 is 2,2-dimethylvinyl and X.sub.2 and X.sub.3 together are .dbd.CH.sub.2 ; or X.sub.1 is 2,2-dimethyloxiranyl, and X.sub.2 and X.sub.3 together are --0--CH.sub.2 --; or X.sub.1 is 1,2-dihydroxy-2-methyl-propyl, X.sub.2 is --CH.sub.2 OH, and X.sub.3 is OH; or X.sub.1 is 2-hydroxy-2-methylpropyl, X.sub.2 is H, and X.sub.3 is CH.sub.2 OH; or X.sub.1 is COOR, and X.sub.2 and X.sub.3 together are .dbd.O, where R is a lower alkyl, phenyl, or benzyl group; or X.sub.1 is 2-methylpropyl, X.sub.2 is H, and X.sub.3 is CH.sub.3. The compound can be produced by culturing Fusarium subglutinans f. sp. tripterygii ATCC 74358 isolated from the stems of Tripterygium wilfordii. A pharmaceutical composition for immunosuppression therapy is prepared containing the compound and a pharmaceutically acceptable vehicle.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.